Tobacco Panelists Under Attack for Drug Industry Ties

An ethics watchdog group filed a complaint yesterday against two panelists on a new federal tobacco products advisory committee, arguing that their links to drug companies present a serious conflict of interest.

According to the filing, the two members of the Food and Drug Administration’s Tobacco Products Scientific Advisory Committee are paid consultants for companies that manufacture or create treatments to help people quit smoking. They also charge hundreds of dollars an hour for providing expert witness testimony for plaintiffs suing tobacco companies, and one is a partner in a company with a nicotine gum patent.

In a statement, Melanie Sloan, the executive director of the Citizens for Responsibility and Ethics in Washington, said: “Loathing tobacco companies does not justify ignoring clear conflicts of interest. As great as it is that the FDA is finally regulating tobacco products…there is no excuse for including those paid to consult or create smoking cessation products on the panel.”

A FDA spokeswoman said that the FDA’s tobacco arm does not regulate tobacco cessation drugs. One of the panelists, Dr. Neal L. Benowitz, told The New York Times that his activities did not present any conflict of interest for the 12-person committee.

“My involvement with pharmaceutical companies is aimed at reducing the risk of smoking, quitting smoking. The aim of the committee is also to reduce the adverse health consequences of tobacco use.”

As The New York Times reports, a subcommittee of the panel will meet today and tomorrow to list the harmful ingredients in tobacco products, and the full committee next month will consider whether the FDA should regulate or ban menthol in cigarettes. The FDA launched the Center for Tobacco Products last year, in order to implement new federal tobacco laws.

In March, the Altria Group, which owns Philip Morris, America’s largest tobacco company, filed a similar challenge, saying that over half of the panel had “financial conflicts and irreconcilable biases.” The FDA rejected the complaint. Two months ago, the FDA also announced plans to increase transparency on advisory committees.

Related: FDA to Increase Transparency on Conflicts of Interest
Are Kids More Likely to Smoke Menthol Cigarettes?
FDA Limits Tobacco Marketing to Kids, Continues Legal Battle


Print Print  

Like what we're doing? We'd appreciate your support.

2 comments to “Tobacco Panelists Under Attack for Drug Industry Ties”

  1. Tobacco news

    Great news! we need to ban all tobacco undustry!

  2. Cigarette Woman

    A very good article, I think people should know what they are smoking and what are the danger they are exposed to.

Leave a comment